Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Neuroscience has announced encouraging final results from a five-year comparative imaging study examining the long-term effect of disease-modifying therapies in treatment-naive, early relapsing-remitting multiple sclerosis patients.
Subscribe to our email newsletter
The study demonstrated that Copaxone treated patients experienced significantly less brain tissue loss, as measured by percent change in brain volume, compared with patients on other disease-modifying therapies.
In the study, patients receiving Copaxone experienced a reduced mean annualized rate of brain atrophy (ARBA) of -0.46% over five years, while patients receiving Avonex or Betaseron/Rebif experienced mean ARBA of -0.52% and -0.64%, respectively. Patients in the untreated control group with an average follow-up of 15.2 months experienced the highest rate of brain atrophy (-0.95%).
Omar Khan, lead investigator of the study, said: “Although patients showed a significantly lower ARBA in all three treatment groups compared with the untreated group, Copaxone-treated patients demonstrated significantly reduced brain atrophy versus patients treated with either low-dose or high-dose interferon-beta.”